Diminished pleiotrophin as a new clue to pre‐eclampsia: Linking impaired angiogenesis to adverse outcomes
International Journal of Gynecology & Obstetrics · 2026-08 · 174 (2) · 953-960
DOI: 10.1002/ijgo.70907 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Gynecology & Obstetrics, online erschienen am 25.02.2026. Verfasst von Muradiye Yildirim und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Perinatology, Ankara Etlik City Hospital, Ankara, Turkey. Hauptthemen laut MEDLINE: Pre-Eclampsia, Carrier Proteins, Cytokines. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Objective
To evaluate maternal serum pleiotrophin (PTN) levels in pregnancies complicated by pre‐eclampsia (PE) and to determine their association with disease severity and adverse perinatal outcomes.
Methods
This prospective case–control study included 45 women diagnosed with mild or severe PE and 45 gestational‐age–matched healthy pregnant controls. Maternal serum PTN levels were measured using enzyme‐linked immunosorbent assay. Demographic, obstetric and neonatal outcomes were compared between groups. Receiver operating characteristic (ROC) analyses were performed to assess the predictive value of PTN for PE, severe PE, and composite adverse perinatal outcomes (CAPO).
Results
Median serum PTN levels were significantly lower in women with PE than in healthy controls (14.47 vs. 30.92 ng/mL; P < 0.001). PTN concentrations were also reduced in severe compared with mild PE (13.43 vs. 29.77 ng/mL; P = 0.019). ROC analysis identified PTN cutoff values of 23.73 ng/mL for PE diagnosis (AUC = 0.703), 20.40 ng/mL for severe PE (AUC = 0.656), and 18.67 ng/mL for CAPO prediction (AUC = 0.667). The PE group had significantly higher rates of preterm birth, fetal growth restriction, neonatal intensive care unit admission, and CAPO.
Conclusion
Decreased maternal serum PTN levels are associated with the presence and severity of pre‐eclampsia, as well as adverse perinatal outcomes. PTN may serve as an additional angiogenic‐related biomarker that complements existing diagnostic tools and improves risk stratification in pregnancies complicated by PE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Perinatology, Ankara Etlik City Hospital, Ankara, Turkey.
- Department of Obstetrics and Gynecology, Ankara Etlik City Hospital, Ankara, Turkey.
ORCID-Profile: Muradiye Yildirim, Ruken Dayanan, Dilara Duygulu Bulan, Nurten Asmali Cilek, Neval Cayonu Kahraman, Belgin Savran Ucok, Sevki Celen, Ali Turhan Caglar
Zitieren
APA
Yildirim, M., Dayanan, R., Duygulu Bulan, D., Asmali Cilek, N., Cayonu Kahraman, N., Savran Ucok, B., Celen, S., & Caglar, A. T. (2026). Diminished pleiotrophin as a new clue to pre‐eclampsia: Linking impaired angiogenesis to adverse outcomes. International Journal of Gynecology & Obstetrics, 174(2), 953-960. https://doi.org/10.1002/ijgo.70907
Vancouver
Yildirim M, Dayanan R, Duygulu Bulan D, Asmali Cilek N, Cayonu Kahraman N, Savran Ucok B, et al. Diminished pleiotrophin as a new clue to pre‐eclampsia: Linking impaired angiogenesis to adverse outcomes. International Journal of Gynecology & Obstetrics. 2026;174(2):953-960. doi:10.1002/ijgo.70907
BibTeX
@article{Yildirim2026,
author = {Yildirim, Muradiye and Dayanan, Ruken and Duygulu Bulan, Dilara and Asmali Cilek, Nurten and Cayonu Kahraman, Neval and Savran Ucok, Belgin and Celen, Sevki and Caglar, Ali Turhan},
title = {Diminished pleiotrophin as a new clue to pre‐eclampsia: Linking impaired angiogenesis to adverse outcomes},
journal = {International Journal of Gynecology & Obstetrics},
year = {2026},
volume = {174},
number = {2},
pages = {953--960},
doi = {10.1002/ijgo.70907}
}
EUVIMED